CYBERDYNE Inc (CYBQF) Fair Value & Analysis
Healthcare · US · Market cap $394M
CYBERDYNE Inc
CYBQF · US
Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Strengths
Risks
Fair value as of: Aug 27, 2026
From 18 valuation models · updated yesterday
Share price +0.8% over the past month.
A solid business, but trading 719% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.2000). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range $1.03 – $5.14 · fair‑value band $0.1200 – $0.2000 · the $1.31 price screens above the $0.1600 fair value. Dashed = 300-day average. As of Aug 27, 2026.
Analysis
CYBERDYNE Inc (CYBQF) currently trades at $1.31, while our model-based Fair Value estimate is $0.1600, implying the stock looks roughly 87.8% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, CYBERDYNE Inc generated revenue of $3.8B at a net margin of 4.0%. Revenue declined 21.6% year over year. It earns a return on equity of 0.4%. The balance sheet holds a net cash position of $8.3B. Fundamentals as of Aug 27, 2026
Our scenario range runs from $0.1200 (bear case) to $0.2000 (bull case); at $1.31, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at -88%, CYBQF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 18 models by family
Widest divergence: Asset-Based ($200.21) versus Earnings-Based ($12.69). Highest evidence: Growth DCF (80).
Notify me when CYBQF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries.
Full company description
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT at home for enhancement of physical functions. In addition, the company provides rescue support in disaster sites, and heavy labor support for factories and plants, as well as engages in the entertainment business. CYBERDYNE Inc. was incorporated in 2004 and is headquartered in Tsukuba, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
CYBERDYNE Inc reported revenue of $3.9B in FY2026 versus $2.2B in FY2022, a compound +15.8%/yr. Reported net income was $154M in FY2026.
CYBQF screens 88% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 364 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $114.10 | $74.79 | -34% |
| Stryker Corporation SYK | $322.12 | $186.28 | -42% |
| Medtronic plc MDT | $89.97 | $65.57 | -27% |
| Boston Scientific Corporation BSX | $48.17 | $30.73 | -36% |
| Edwards Lifesciences Corporation EW | $90.78 | $41.02 | -55% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | -14% |
| DexCom, Inc DXCM | $88.96 | $38.95 | -56% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare CYBERDYNE Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CYBERDYNE Inc (CYBQF) overvalued or undervalued?
What is the fair value of CYBQF?
What is the quality score of CYBQF?
What is the revenue of CYBERDYNE Inc (CYBQF)?
What is the net profit margin of CYBQF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch CYBERDYNE Inc in the live analysis
One click puts CYBERDYNE Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.